drugset
drugset / Trial / NCT02580006

To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers

NCT02580006 ↗

Phase 1 Unknown 42 enrolled Dong-A ST Co., Ltd.
RandomizedCrossoverDouble-blindTreatment

Summary

This Phase I study is to compare pharmacokinetics, safety and pharmacodynamics of EPORON and EPREX after single subcutaneous administration.

Timeline

Start
2015-11
Primary completion
2016-01
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 4000 iu Subcutaneous

Indications

No indication recorded.